marked.bio

BRAF inhibitor (paradox breaker, brain-penetrant) · small molecule

HSK42360

4 active trials, targeting BRAF. Not approved for any biomarker on marked.bio yet.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
BRAF V600E 4 4 Phase 1/2

Sponsors

Industry sponsors leading active biomarker-selected trials of HSK42360.

  1. Haisco Pharmaceutical Group 4

Trials

4 of 4 trials shown

  1. HSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in BRAF V600-Mutant Metastatic Colorectal Cancer

    Recruiting Phase 1/2 Haisco Pharmaceutical Group Started 2026Primary completion 2029-09 NCT07790510

    HSK42360cetuximab FDA EUmFOLFOX6oxaliplatinleucovorinfluorouracilFOLFIRIirinotecan

    … (limited to PCR or NGS-based assays) must be provided prior to enrollment to demonstrate BRAF V600 mutation positivity;

    BRAF V600EMetastatic Colorectal Cancer (CRC)

  2. Phase I Study of HSK42360-Na in Solid Tumors With BRAF V600 Mutation

    Recruiting Phase 1 Haisco Pharmaceutical Group Started 2026Primary completion 2028-12 NCT07561554

    HSK42360

    Positive BRAF V600 mutation result confirmed prior to the administration of HSK42360-Na.

    BRAF V600ESolid Tumors (Phase 1)

  3. Phase I Study of HSK42360 in Malignant Brain Tumors With BRAF V600 Mutation

    Recruiting Phase 1 Haisco Pharmaceutical Group Started 2025Primary completion 2029-05 NCT07158710

    HSK42360

    Positive BRAF V600 mutation result confirmed prior to the administration of HSK42360.

    BRAF V600EMalignant Brain Tumors

  4. Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation

    Recruiting Phase 1 Haisco Pharmaceutical Group Started 2024Primary completion 2026-08 NCT06536400

    HSK42360

    Positive BRAF V600 mutation result confirmed prior to the administration of HSK42360.

    BRAF V600EStatus may be outdated, last updated 2024-08-05Solid Tumors